<DOC>
	<DOCNO>NCT01850745</DOCNO>
	<brief_summary>Adherence antiviral treatment chronic hepatitis C ( CHC ) important factor achieve sustain virological response ( SVR ) . The aim study evaluate efficacy multidisciplinary support program ( MSP ) adherence efficacy pegylated interferon alfa-2a ribavirin compare conventional approach . We assess 447 patient CHC receive antiviral treatment distribute 3 group : control group ( recruit 2002-2004 , n= 147 ) , MSP-pilot group ( recruit 2005-2006 , n=131 ) , MSP-validation group ( recruit 2007-2009 , n=169 ) .</brief_summary>
	<brief_title>Multidisciplinary Support Program Chronic Hepatitis C</brief_title>
	<detailed_description>Adherence antiviral treatment chronic hepatitis C ( CHC ) important factor achieve sustain virological response ( SVR ) . The aim study evaluate efficacy multidisciplinary support program ( MSP ) adherence efficacy pegylated interferon alfa-2a ribavirin compare conventional approach . We assess 447 patient CHC receive antiviral treatment distribute 3 group : control group ( follow-up 2002-2004 , n= 147 ) , MSP-pilot group ( follow-up 2005-2006 , n=131 ) , MSP-validation group ( follow-up 2007-2009 , n=169 ) .A cost-effectiveness analysis perform use Markov model .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Patients chronic hepatitis C eligible receive antiviral treatment . Patients undergone previous antiviral treatment , human immunodeficiency virus ( HIV ) hepatitis B virus ( HBV ) coinfection , individual include treatment protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Chronic hepatitis C virus infection ( CHC )</keyword>
</DOC>